Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:HPTX

(HPTX) (HPTX) Stock Price, News & Analysis

(HPTX) logo

About (HPTX) Stock (NASDAQ:HPTX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
786,899 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company's products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company's products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Receive HPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (HPTX) and its competitors with MarketBeat's FREE daily newsletter.

HPTX Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
See More Headlines

HPTX Stock Analysis - Frequently Asked Questions

(HPTX) (NASDAQ:HPTX) announced its quarterly earnings data on Thursday, February, 26th. The biopharmaceutical company reported $0.47 earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.67. The business's revenue was up 65.6% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that (HPTX) investors own include Tivity Health (TVTY), Bausch Health Companies (BHC), Berkshire Hills Bancorp (BHLB), Cognex (CGNX), The Cigna Group (CI), Cynosure (CYNO) and Depomed (DEPO).

Company Calendar

Last Earnings
2/26/2015
Today
6/06/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:HPTX
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:HPTX) was last updated on 6/6/2025 by MarketBeat.com Staff
From Our Partners